Zydus Cadila receives US FDA approval for cholestyramine suspension

It is indicated as an adjunctive therapy for reduction of elevated serum cholesterol in patients

Pfizer stops production of Corex cough syrup

Premium

BS B2B Bureau Ahmedabad

Last Updated : May 02 2017 | 1:26 PM IST

Zydus Cadila has received the final approval from the US Food & Drug Administration (FDA) to market cholestyramine for oral suspension USP (4 gm per scoopful).

It is indicated as an adjunctive therapy to the diet for the reduction of elevated serum cholesterol in patients with primary hypercholesteolemia - elevated low density lipoprotein (LDL) cholesterol - who do not respond adequately to diet. Cholestyramine will be produced at the group’s formulations manufacturing facility at Baddi.

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in